Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Based on the possibilities that both plasma and circulating tumor cells (CTCs) (the "liquid
biopsy") may offer, we consider that it could be feasible to longitudinally monitor the
genetic evolution and the biologic characteristics of CTCs, by using Circulating tumor DNA
(ctDNA) and CTCs as a source of biologic material. This approach could provide information
regarding the genetic/molecular changes associated with primary and acquired resistance to
AZD9291 and, thus, to facilitate to more appropriately adapt the tailored treatment in this
particular group of NSCLC patients. It has been recently reported that the detection of
resistant clones, based on the tumor-associated genetic aberrations in the blood, can
identify treatment resistance up to 10 months earlier than the radiological methods
providing, thus, the potential for an early switch to a non cross-resistant therapy in order
to improve patients' outcome.